Table 1.

Clinical details of study participants.

Patient Code	Specimen description	Sex	Age at diagnosis	Tissues affected	Treatment prior to specimen	Age at specimen	Disease status at specimen	Sequelae, other comments
1	Bone lesion	M	68	Bone	Previous irradiation at site of and excision of hip lesion	68	Active (AD)	Diabetes insipidus from age 55
1	Matched blood
2	Pulmonary lesion	M	40	Lung	Nil	40	AD	Mild pulmonary fibrosis, smoker
2	Matched blood
3	Involved lymph node	M	9	Bone, lymph node	Nil	9	AD	Skull defect
4	Blood	M	18 months	Skin	Nil	13	Non-active (NAD)
5	Blood	M	53	Bone, lung, bone marrow	Vinblastine/prednisolone	64	NAD	Mild pulmonary fibrosis
6	Blood	M	39	Lung	Vinblastine/prednisolone	52	NAD
7	Blood	F	60	Skin	Methotrexate/prednisolone	64	NAD	Leg scarring
8	Blood	F	36	Bone	Lesion excision	37	NAD
9	Blood	F	25	Bone	Vinblastine/prednisolone	42	NAD	Ataxia at time of specimen
10	Blood	M	41	Skin	Nil	41	AD
11	Blood	F	39	Bone, lung	Nil	39	AD
12	Blood	F	34	Lung	Biopsy and vinblastine/prednisolone	54	NAD	Long term pulmonary fibrosis
13	Bone lesion	M	2	Bone	Nil	2	AD	Mutation in BRAFV600, CNS-risk lesion
13	Matched blood
14	Blood	M	8 months	Skin, lymph node, liver	Nil	22 months	AD	No detectable mutation in BRAFV600
15	Blood	M	10	Bone, skin	Cytarabine, prednisolone and vinblastine (ceased 6 months prior to specimen)	12	AD	Diabetes insipidus, mutation in BRAFV600
16	Blood	M	67	Bone, skin	Nil	67	NAD